QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
Status:
Active, not recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination
therapy in subjects with SCC who have progressed on or after previous platinum-based
chemotherapy and anti-PD-1/PD-L1 therapy. Phase 2 will be based on Simon's two-stage optimal
design.